India's drug pricing authority caps trade margins on 137 cancer drugs at 30%

The Economic Times reports India’s National Pharmaceutical Pricing Authority capped trade margins on 137 anti-cancer drugs at 30% of the maximum retail price, excluding GST. Revised prices are set to take effect November 9, 2026. Manufacturers must lower prices above the newly calculated maximum and maintain existing prices that are lower. The list includes atezolizumab and bevacizumab but excludes Keytruda.